DGAP-News: Hitachi Chemical Co., Ltd. / Key word(s): Miscellaneous
23.09.2020 / 08:00
The issuer is solely responsible for the content of this announcement.
FOR IMMEDIATE RELEASE
Hitachi Chemical’s Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine
ALLENDALE, NJ., USA, MUNICH, GERMANY, and YOKOHAMA, JAPAN – Sept. 23, 2020-
The regenerative medicine business of Hitachi Chemical Co., Ltd. (“Hitachi Chemical”) announces that, effective today, it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.
“By working and using the single name Minaris Regenerative Medicine, we will strengthen our brand perception and recognition as a unified, global CDMO, intensify our cooperation with and further expand our integrated services for our clients,” said Kazuchika Furuishi, PhD, Corporate Officer and General Manager, Regenerative Medicine Business Sector of Hitachi Chemical and CEO of Minaris Regenerative Medicine, LLC. “With this change,